Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age from 60 days to 90 days;~* Adults, parent(s) or guardians are able to understand and sign informed consent for participation;~* Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;~* Infants no vaccinated with poliovaccine or other preventive biologicals in recent 7 days;~* Axillary temperature ≤37℃.~Exclusion Criteria:~* Have medical record of participants or their family on allergy, convulsion, falling sickness, encephalopathy and psychopathy;~* Low platelet or bleeding disorder do not allow vaccination into the muscle;~* Have damaged or lower immunological function;~* Received blood, plasma or immunoglobulin treatment since birth;~* Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );~* Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.~Exclusion Criteria for doses 2 and 3~* Have serious anaphylaxis or high fever, convulsion during first dose;~* Have any circus of Exclusion Criteria after Eligible for study;~* Have serious adverse event which related to previous vaccination; Withdrawal and Discontinuance Criteria;~* Received necessary or interference study drugs such as: immune-inhibition or immune-stimulating agents;~* Vaccinated with any other vaccine（except DTP）;~* Stop observation determined by investigator owing to occurring serious adverse event.

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
- Cohort 2: (Type: EXPERIMENTAL): Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).